Clinical outcomes of treatments for patients with refractory metastatic colorectal cancer: a systematic literature review and network meta-analysis.

ABSTRACT:

Background

For metastatic colorectal cancer (mCRC) patients whose disease is refractory to standard therapies, treatment with regorafenib, fruquintinib, or trifluridine/tipiracil (FTD/TPI; also known as TAS-102) with or without bevacizumab is recommended. Recent clinical trial evidence indicates that FTD/TPI + bevacizumab has superior efficacy to FTD/TPI for these patients, although its relative efficacy compared with other treatment regimens requires further evidence.

Objectives

A systematic literature review (SLR) and network meta-analysis (NMA) were performed to evaluate the relative efficacy of treatments for patients with refractory mCRC.

Design

SLR and NMA.

Data sources and methods

Databases were searched for clinical trials evaluating treatments for refr

SUBMITTER: Taieb J 

PROVIDER: S-EPMC12833170 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature